Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

 
• By Joseph Haas
  
businessman and businesswoman are exchanging document or contract
Ovid/Angelini partnership is the first deal for an Angelman syndrome therapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business